はしか(Measles)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Measles Overview 8
Therapeutics Development 9
Pipeline Products for Measles – Overview 9
Pipeline Products for Measles – Comparative Analysis 10
Measles – Therapeutics under Development by Companies 11
Measles – Therapeutics under Investigation by Universities/Institutes 12
Measles – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Measles – Products under Development by Companies 17
Measles – Products under Investigation by Universities/Institutes 18
Measles – Companies Involved in Therapeutics Development 19
Beijing Tiantan Biological Products Co., Ltd. 19
Biological E. Limited 20
China National Pharmaceutical Group Corporation 21
GlaxoSmithKline plc 22
Prometheon Pharma, LLC 23
Serum Institute of India Limited 24
Universal Stabilization Technologies, Inc. 25
Vical Incorporated 26
Zydus Cadila Healthcare Limited 27
Measles – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
(measles [schwarz strain] + mumps [RIT 4385 strain] + rubella [wistar RA 27/3 strain])vaccine – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
AS-136A – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cell Therapy for Measles, Mumps and Rubella – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ERDRP-0519 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
measles + mumps + rubella + varicella vaccine – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
measles + mumps + rubella + varicella vaccine – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
measles + mumps + rubella vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
measles + mumps + rubella vaccine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
measles + rubella vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
measles + rubella vaccine – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
measles + rubella vaccine – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
measles [edmonston – zagreb strain] vaccine – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
measles vaccine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
measles vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
measles vaccine – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
measles vaccine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Measles – Recent Pipeline Updates 54
Measles – Dormant Projects 55
Measles – Product Development Milestones 56
Featured News & Press Releases 56
Nov 24, 2014: Powdered Measles Vaccine Found Safe In Early Clinical Trials 56
Aug 21, 2008: Vaxfectin Formulated Measles DNA Vaccine Could Address Unmet Need for Infants 57
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59